Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 15 The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Authors Dong M , Wen S , Zhou L Received 21 May 2022 Accepted for publication 12 August 2022 Published 22 August 2022 Volume 2022:15 Pages 25832597 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Professor Ming-Hui Zou Meiyuan Dong, 1 Song Wen, 1 Ligang Zhou 1, 2 1 Department of Endocrinology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 201399, Peoples Republic of China
GLP-1 medications have received a lot of well-deserved attention for the seemingly miraculous way they support weight management
A young child's brain is especially dependent on receiving ample amounts of oxygen and energy for proper growth and development
When GLP-1 drugs are covered for diabetes treatment, almost all plans use at least one utilization management strategy to control costs, such as prior authorization or quantity limits
Por lo que es necesaria su unin con la carnitina para formar un complejo permeable (acil-carnitina) a partir de la enzima carnitina palmitoil transferasa I y poder acceder al interior de la mitocondria
Inflammation is when the body notices the damage and sends the inflammatory cells to the injured site, preparing for the regeneration process
